|
Novel Endoglycosidase Derivatives Treating Diseases of the Adaptive Immune System
Application
Protein-based therapeutics for the treatment of IgG-mediated diseases.
Key Benefits
A new class of endoglycosidases for the treatment of IgG-mediated diseases.
Four novel compounds have been developed that exhibited robust in vitro activity.
Potential to become first-in-class medications for dysregulation of the adaptive immune system,...
Published: 11/20/2024
Contributor(s): Eric Sundberg, Diego Sastre, Jonathan Du, Jeffrey Ravetch, Stylianos Bournazos
|
|
Whole-Animal Genetic Model to Mimic Aspects of the Patient Phenotype of Classic Galactosemia
Application
An animal model for studying the underlying causes of galactosemia and screening for novel drugs to treat the condition.
Key Benefits
The first animal model for elucidating the underlying causes of galactosemia in infants.
Animals with galactosemia causing genetic knockout exhibit similar disease phenotypes and complications...
Published: 7/30/2024
Contributor(s): Judith Fridovich-Keil
|
|
Functionalized Collagen Biochips with Core-Shell Structures and Collagen-Mimetic Peptide Nanotubes
Application
Synthetic collagen-based biomaterials for therapeutic delivery or drug testing.
Key Benefits
Synthetic collagen substitute.
Capable of formulating into various structures.
Free of animal-based contaminants.
Able to be spatially patterned.
Market Summary
Organ failure and tissue defects affect millions of Americans, resulting in...
Published: 11/20/2024
Contributor(s): Vincent Conticello, Andrea Merg, Gavin Touponse
|
|
KRAS Mutant Protein-Protein Interaction Targets and Inhibitors for Cancer Therapy
Application
Immunotherapeutic agent and biosensor for KRASG12V mutation in tumor cells.
Key Benefits
First in class, targeted immunotherapy for patients presented with KRASG12V mutation.
Attenuates immune suppression associated with KRASG12V-positive cancers.
Market Summary
The KRASG12V mutation, representing 85% of all cancer mutations, is...
Published: 11/20/2024
Contributor(s): Haian Fu, Cong Tang, Xiulei Mo
|
|
Caspase-3 Deficient MEFs with Mutant Caspase-3 Re-Introduced
Application
Mouse embryonic fibroblast (MEF) line deficient in caspase-3 that are reconstituted with constitutively expressed mutant versions of the protease.
Key Benefits
An immortalized caspase-3-deficient MEF cell line.
Tool to study protease induced apoptosis.
Technical Summary
Emory inventors have discriminated a previously unknown role...
Published: 9/26/2024
Contributor(s): Lawrence Boise, Katelyn Ponder
|
|
Photocaged Cytokines for Cancer Immunotherapy
Application
Light-responsive cytokine prodrugs with controlled activation for improved cancer immunotherapy.
Key Benefits
Spatiotemporal control of therapeutic cytokine activation leads to controlled local activation and reduces off-target toxicity.
Prolonged circulation means less frequent dosing is required.
Biased activity towards CD8+ T-cells...
Published: 11/20/2024
Contributor(s): Erik Dreaden, Lacey Perdue, Priscilla Do
|
|
Ribosome Pegging: An Antibiotic-free System to Produce Recombinant Proteins
Application
Antibiotic-free method to prevent the growth of cells that fail to express high levels of a non-essential protein (target protein).
Key Benefits
Prevents the use of antibiotics and markers that promote resistance.
Facilitates the deployment of recombinant bacteria in uncontrolled environments.
Stabilizes heterologous expression of...
Published: 9/26/2024
Contributor(s): Ichiro Matsumura
|
|
Strategy to Identify miRNAs for Disease Diagnosis
Application
Method to measure precursor and mature miRNA specifically.
Key Benefits
Unique primers can specifically identify miRNAs and precursor miRNAs by standard qRT-PCR without the requirement for an additional detection probe.
Allows for amplification and quantification of both mature miRNA and precursor miRNAs.
Potential technology to evaluate...
Published: 9/26/2024
Contributor(s): Wenming Li
|
|
Selective Enrichment of A-To-I Edited Transcripts from Cellular RNA Using Endonuclease V
Application
Kit to efficiently identify and enrich adenosine-to-inosine (A-to-I) editing in RNA molecules.
Key Benefits
Robust and facile method for enriching A-to-I edited transcripts.
Overcomes the low efficiency and accuracy of transcriptome-wide RNA-seq.
Market Summary
A-to-I RNA editing by adenosine deaminases is a common RNA modification...
Published: 10/28/2024
Contributor(s): Steven Knutson, Jennifer Heemstra
|
|
Cas9 Controlled Gene Activation
Application
Flexible system using Cas9 to modulate gene expression.
Key Benefits
Edits genes by cleaving DNA as well as inhibiting transcription.
No need to transfect cells with additional Cas9.
Market Summary
The CRISPR-Cas9 system is a bacterial adaptive immune system that has been appropriated for genetic engineering. The CRISPR-Cas9 system...
Published: 10/28/2024
Contributor(s): David Weiss, Hannah Ratner
|
